A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Mean eGFR greater than or equal to 30 mL/min/1.73m2
• Clinical evidence of active kidney disease
• Treated with supportive care including an ACE inhibitor or ARB if applicable
• Willing to receive required vaccinations
• Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Locations
Other Locations
China
ADARx Clinical Site
NOT_YET_RECRUITING
Baotou
ADARx Clinical Site
RECRUITING
Beijing
ADARx Clinical Site
NOT_YET_RECRUITING
Shenzhen
ADARx Clinical Site
RECRUITING
Wuxi
ADARx Clinical Site
RECRUITING
Yantai
Contact Information
Primary
Stephanie Leyva
sleyva@adarx.com
877-232-7974
Time Frame
Start Date: 2026-07-23
Estimated Completion Date: 2029-01-21
Participants
Target number of participants: 30
Treatments
Experimental: Part A - ADX-038 Monotherapy
Experimental: Part B - ADX-038 Combination Therapy
Related Therapeutic Areas
Sponsors
Leads: ADARx Pharmaceuticals, Inc.